Key result
Trimetazidine add-on linked to higher SOD activity and faster sialic acid normalization in MI.
Why the study?
Metabolic therapy with agents like trimetazidine is a relatively new option for ischemic heart disease, and its beneficial effects as add-on therapy in myocardial infarction patients require assessment.
Does trimetazidine added to conventional medical therapy improve antioxidant capacity (SOD and TSA levels) in patients with myocardial infarction?
Observational
Does trimetazidine added to conventional medical therapy improve antioxidant capacity (SOD and TSA levels) in patients with myocardial infarction?
Trimetazidine added to conventional therapy in myocardial infarction patients may reduce free radical production and restore antioxidant capacity.
Trimetazidine was associated with improved antioxidant markers post-MI; hypothesis-generating and should not yet change practice.
Metabolic therapy constitutes a relatively new therapeutic option for ischemic heart disease (IHD). Metabolic agents including Trimetazidine [1-(2,3,4-trimethoxybenzyl) piperazine] (TMZ) are currently used as anti-ischemic cardiac drugs to alleviate this internal metabolic disturbance. The present study focused on the assessment of the beneficial effects of TMZ as additional medication to the conventional medical therapy in patients with myocardial infarction. The obtained results showed an increase of superoxide dismutase (SOD) activities and a faster normalization of total sialic acid (TSA) levels in patients with TMZ add-on therapy, in comparison to the control group, indicating a stabilization of the ischemic process under TMZ therapy, with decreased free radical production and restoration of the antioxidant capacity and of the membrane lesions. The present findings emphasize the importance of TMZ administration to prevent reperfusion-mediated cardiac injury and dysfunction and demonstrate that this promising therapeutic approach is worthy of further research.
No takes yet. Share an insight, caveat, or question.
Ivan et al. (2018) conducted an observational in Myocardial infarction. Trimetazidine vs. Control group (conventional medical therapy alone) was evaluated on Superoxide dismutase (SOD) activities and total sialic acid (TSA) levels. Trimetazidine add-on therapy increased superoxide dismutase activities and led to faster normalization of total sialic acid levels compared to control in patients with myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: